Novo Holdings Finalizes $16.5 Billion Acquisition of Catalent Novo Holdings has completed its $16.5 billion all-cash acquisition of Catalent, transitioning the drug manufacturer to private ownership. Catalent’s stock has been delisted from the NYSE, with shareholders receiving $63.50 per share. Post-acquisition, Novo Nordisk will acquire three Catalent manufacturing sites, solidifying strategic industry shifts.123